NasdaqCM:CRIS 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費
31 Mar 24	10	-48	19
31 Dec 23	10	-47	19
30 Sep 23	10	-47	18
30 Jun 23	10	-48	18
31 Mar 23	10	-52	19
31 Dec 22	10	-57	20
30 Sep 22	10	-59	20
30 Jun 22	11	-57	20
31 Mar 22	11	-52	19
31 Dec 21	11	-45	17
30 Sep 21	11	-39	16
30 Jun 21	10	-34	14
31 Mar 21	10	-30	13
31 Dec 20	11	-30	12
30 Sep 20	11	-31	12
30 Jun 20	11	-31	12
31 Mar 20	11	-32	12
31 Dec 19	10	-32	12
30 Sep 19	9	-29	12
30 Jun 19	9	-30	13
31 Mar 19	10	-32	14
31 Dec 18	10	-33	15
30 Sep 18	11	-35	15
30 Jun 18	11	-43	14
31 Mar 18	10	-48	15
31 Dec 17	10	-53	14
30 Sep 17	9	-57	15
30 Jun 17	8	-70	16
31 Mar 17	8	-67	16
31 Dec 16	8	-60	16
30 Sep 16	7	-63	15
30 Jun 16	8	-40	13
31 Mar 16	8	-37	13
31 Dec 15	8	-59	13
30 Sep 15	8	-51	13
30 Jun 15	7	-51	13
31 Mar 15	10	-45	12
31 Dec 14	10	-19	12
30 Sep 14	9	-17	11
30 Jun 14	15	-14	12
31 Mar 14	15	-13	12
31 Dec 13	15	-12	11
30 Sep 13	15	-20	11

質の高い収益: CRISは現在利益が出ていません。

利益率の向上: CRISは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: CRISは利益が出ておらず、過去 5 年間で損失は年間13.4%の割合で増加しています。

成長の加速: CRISの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CRISは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: CRISは現在利益が出ていないため、自己資本利益率 ( -504.44% ) はマイナスです。

Curis 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Curis, Inc. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Curis, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Curis, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Recent updates

Curis, Inc. Announces Additional Data from Take Aim Leukemia Study

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Curis, Inc. to Report Q1, 2024 Results on May 07, 2024

Price target decreased by 22% to US$77.40

Curis, Inc., Annual General Meeting, May 21, 2024

Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Consensus EPS estimates upgraded to US$6.06 loss

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 28%, EPS downgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

Curis, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Curis, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study

New major risk - Share price stability

Price target increased by 18% to US$180

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate

Curis, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Curis, Inc. to Report Q2, 2023 Results on Aug 03, 2023

U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID

Consensus EPS estimates fall by 12%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Curis, Inc. Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Price target increased to US$15.33

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$12.25

Curis, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Curis Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price

Curis, Inc. Elects Anne E. Borgman as Class I Director

Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Curis, Inc. Announces That the U.S. Food and Drug Administration (FDA) Has Notified Curis That It May Resume Enrollment of Additional Patients in the Monotherapy Phase of the TakeAim Leukemia Study

FDA Lifts Partial Clinical Hold on the Takeaim Lymphoma Study of Emavusertib of Curis, Inc

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Price target increased to US$17.67

Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Curis, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Curis: Asymmetric Risk And Reward

Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022

Curis, Inc.(NasdaqGM:CRIS) dropped from Russell 3000E Growth Index

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

Consensus EPS estimates fall by 14%

Price target increased to US$15.75

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$14.20

Curis, Inc., Annual General Meeting, May 26, 2022

Curis, Inc. Announces FDA Partial Clinical Hold for on the Company’s Takeaim Lymphoma Phase 1/2 Study

Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Curis, Inc. Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations

Curis, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Relapsed or Refractory Solid Tumors

Checking In On Curis

Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.11 loss in 3Q 2020)

Insufficient new directors

Insufficient new directors

We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth

Curis Inc.: Revisiting CA-4948 After Q2 Update

過去基準チェック /06